Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Somar Corporation has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, so the recorded prosecution activity is divided across separate examination paths.
LI, WENHAN is the busiest examiner, with 1 pending matter. Counsel should prepare matter-specific responses while checking whether the two applications share technical disclosures or claim language that would benefit from a consistent position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, WENHAN | 1 | — | — |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16457308 | MATERIAL FOR TREATMENT OF BRAIN INJURY, METHOD FOR TREATMENT OF BRAIN INJURY, MATERIAL FOR REGENERATION OF BRAIN NEURONS, AND METHOD FOR REGENERATION OF BRAIN NEURONS | WANG, CHANG YU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16457308 | MATERIAL FOR TREATMENT OF BRAIN INJURY, METHOD FOR TREATMENT OF BRAIN INJURY, MATERIAL FOR REGENERATION OF BRAIN NEURONS, AND METHOD FOR REGENERATION OF BRAIN NEURONS | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19120654 | ANTIFIBROTIC AGENT, PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS, AND METHOD FOR INACTIVATING MYOFIBROBLASTS | LI, WENHAN | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 11, 2025 |
| 16457308 | MATERIAL FOR TREATMENT OF BRAIN INJURY, METHOD FOR TREATMENT OF BRAIN INJURY, MATERIAL FOR REGENERATION OF BRAIN NEURONS, AND METHOD FOR REGENERATION OF BRAIN NEURONS | WANG, CHANG YU | 1675 | §103§112 | Final Rejection | — | Pending | Jun 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSomar Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Wenhan Li has the most, with 1 of Somar Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
